文献速递消化系统肿瘤

FOLFIRINOX新辅助后个体化放化疗治疗交界可切除胰腺癌的2期试验

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
PubMed 文献 · JAMA Oncol · 2018-01-01

该单臂2期试验纳入48例交界可切除胰腺导管腺癌患者,术前接受8周期FOLFIRINOX后根据血管受累情况给予个体化放化疗。主要终点R0切除率为65%(95%CI 49%-78%),可切除者中R0率97%;中位PFS 14.7个月,中位OS 37.7个月,支持开展3期试验。

要点

  • 术前FOLFIRINOX联合个体化放化疗使65%交界可切除胰腺癌患者达到R0切除。
  • 全部可切除患者中R0切除率高达97%,中位PFS 48.6个月。
  • 全组中位OS 37.7个月,2年OS率56%,疗效支持3期试验验证。

核心结论

  • 交界可切除胰腺癌术前FOLFIRINOX后个体化放化疗可获得高R0切除率和延长的中位PFS及OS,支持开展3期试验。

研究设计与样本

  • 单臂2期临床试验,2012年8月3日至2016年8月31日在一家大型学术医院纳入48例新诊断、未经治疗、多学科评估为交界可切除的局部胰腺癌患者。
  • 患者ECOG体力状态0或1,血液、肾脏和肝脏功能充分;分析时30例存活者中位随访18.0个月。

主要发现

  • 48例 eligible 患者中31例(65%;95%CI 49%-78%)达到R0切除;32例接受切除者中R0率为97%(n=31)。
  • 全部 eligible 患者中位PFS为14.7个月(95%CI 10.5至未达到),2年PFS率43%;中位OS为37.7个月(95%CI 19.4至未达到),2年OS率56%。
  • 接受切除患者中位PFS为48.6个月(95%CI 14.4至未达到),中位OS未达到,2年PFS率55%,2年OS率72%。
  • 计划接受8周期术前化疗的43例中34例(79%)完成全部周期;27例(56%)接受短程放化疗,17例(35%)接受长程放化疗。

关键数值与推荐

  • R0切除定义及评估方法原文未详述;主要终点为R0切除率,次要终点为中位PFS和中位OS。
  • 短程放化疗方案为5 Gy×5质子放疗联合卡培他滨;长程放化疗为氟尿嘧啶或卡培他滨联合放疗。

临床怎么用

  • 对交界可切除胰腺癌可考虑术前FOLFIRINOX联合个体化放化疗的新辅助治疗策略,以提高R0切除率。
  • 根据血管受累是否消退选择短程或长程放化疗,实现个体化治疗。

局限性

  • 单臂2期试验,无对照组,样本量48例,结论需3期随机试验验证。
  • 单中心研究,随访时间有限(存活者中位随访18.0个月),长期生存数据尚不成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with borderline-resectable pancreatic ductal adenocarcinoma have historically poor outcomes with surgery followed by adjuvant chemotherapy. Evaluation of a total neoadjuvant approach with highly active therapy is warranted. OBJECTIVE: To evaluate the margin-negative (R0) resection rate in borderline-resectable pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin) therapy and individualized chemoradiotherapy. DESIGN, SETTING, AND PARTICIPANTS: A single-arm, phase 2 clinical trial was conducted at a large academic hospital with expertise in pancreatic surgery from August 3, 2012, through August 31, 2016, among 48 patients with newly diagnosed, previously untreated, localized pancreatic cancer determined to be borderline resectable by multidisciplinary review, who had Eastern Cooperative Oncology Group performance status 0 or 1 and adequate hematologic, renal, and hepatic function. Median follow-up for the analysis was 18.0 months among the 30 patients still alive at study completion. INTERVENTIONS: Patients received FOLFIRINOX for 8 cycles. Upon restaging, patients with resolution of vascular involvement received short-course chemoradiotherapy (5 Gy × 5 with protons) with capecitabine. Patients with persistent vascular involvement received long-course chemoradiotherapy with fluorouracil or capecitabine. MAIN OUTCOMES AND MEASURES: The primary outcome was R0 resection rate; secondary outcomes were median progression-free survival (PFS) and median overall survival (OS). RESULTS: Of the 48 eligible patients, 27 were men and 21 were women, with a median age of 62 years (range, 46-74 years). Of the 43 patients who planned to receive 8 preoperative cycles of chemotherapy, 34 (79%) were able to complete all cycles. Twenty-seven patients (56%) had short-course chemoradiotherapy, while 17 patients (35%) had long-course chemoradiotherapy. R0 resection was achieved in 31 of the 48 eligible patients (65%; 95% CI, 49%-78%). Among the 32 patients who underwent resection, the R0 resection rate was 97% (n = 31). Median PFS among all eligible patients was 14.7 months (95% CI, 10.5 to not reached), with 2-year PFS of 43%; median OS was 37.7 months (95% CI, 19.4 to not reached), with 2-year OS of 56%. Among patients who underwent resection, median PFS was 48.6 months (95% CI, 14.4 to not reached) and median OS has not been reached, with a 2-year PFS of 55% and a 2-year OS of 72%. CONCLUSIONS AND RELEVANCE: Preoperative FOLFIRINOX followed by individualized chemoradiotherapy in borderline resectable pancreatic cancer results in high rates of R0 resection and prolonged median PFS and median OS, supporting ongoing phase 3 trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01591733.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Murphy JE, Wo JY, Ryan DP, et al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018. PMID: 29800971. doi:10.1001/jamaoncol.2018.0329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。